Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
34.26
-0.01 (-0.03%)
At close: Nov 21, 2025, 4:00 PM EST
34.29
+0.03 (0.08%)
After-hours: Nov 21, 2025, 7:59 PM EST
Viking Therapeutics Employees
Viking Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 9 or 33.33% compared to the previous year.
Employees
36
Change (1Y)
9
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$6,594,278
Market Cap
3.87B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36 | 9 | 33.33% |
| Dec 31, 2023 | 27 | 6 | 28.57% |
| Dec 31, 2022 | 21 | 3 | 16.67% |
| Dec 31, 2021 | 18 | -2 | -10.00% |
| Dec 31, 2020 | 20 | 1 | 5.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VKTX News
- 7 hours ago - 3 Weight-Loss Drug Stocks To Consider For 2026 - Benzinga
- 2 days ago - Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 days ago - Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 - PRNewsWire
- 15 days ago - Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025 - PRNewsWire
- 16 days ago - Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain - Benzinga
- 17 days ago - Viking Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 23 days ago - Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025 - PRNewsWire
- 4 weeks ago - Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith) - Seeking Alpha